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Pregnancy affects both the maternal and fetal metabolism and even in nondiabetic women exerts a diabetogenic
effect. Among pregnant women, 2 to 17.8% develop gestational diabetes. Pregnancy can also occur in women with
preexisting diabetes, that can predispose the fetus to many alterations in organogenesis, growth restriction and the
mother to some diabetes-related complications like retinopathy and nephropathy or accelerate the course of these
complications if they are already present. Women with gestational diabetes generally start their treatment with diet
and lifestyle modification; when these changes fail in keeping an optimal glycemic control, then insulin therapy
must be considered. Women with type 2 diabetes in use of oral hypoglycemic agents are advised to change to
insulin therapy. Those with preexisting type 1 diabetes must start an intensive glycemic control, preferably before
conception. All these procedures are performed aiming to keep glycemic levels normal or near-normal as possible
to avoid the occurrence of adverse perinatal outcomes to the mother and to the fetus. The aim of this review is to
reinforce the need to improve the knowledge on reproductive health of women with diabetes during gestation
and to understand what are the reasons for them failing to attend for prepregnancy care programs, and to
understand the underlying mechanisms of adverse fetal and maternal outcomes, which in turn may lead to
strategies for its prevention.
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Pregnancy affects both the maternal and fetal metabol-
ism and even in nondiabetic women exerts a diabeto-
genic effect. As normal pregnancy progresses insulin
resistance increases and pancreatic β-cells reserve is
stressed aiming to maintain glycemia within normal
ranges; gestational diabetes results when β-cells fail to
maintain glycemia in these ranges. At delivery, when the
placenta that exerts the major anti-insulin effect is
removed, usually glucose homeostasis is restored. How-
ever, 2 to 17.8% of women develop gestational diabetes,
depending on the diagnostic criteria used and the stud-
ied population; gestational diabetes represents a very
strong predictor for the development of permanent dia-
betes later in life [1].
Besides gestational diabetes, pregnancy can also occur
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reproduction in any medium, provided the orin preexisting diabetes during pregnancy has been
observed in the USA between 1999 and 2005, rising from
10% to 21% [2]. Pregestational diabetes, both type 1 and
type 2 can cause alterations from fertilization, through all
pregnancy period and even after its end. It can predispose
the fetus to many alterations in organogenesis, growth re-
striction and predispose the mother to some diabetes-
related complications like retinopathy and nephropathy
or accelerate the course of these complications if they
are already present. Gestational diabetes generally
leads to fetal growth alterations [1].
The aim of this review is to report the literature on the
great incidence of maternal and fetal adverse pregnancy
outcomes found nowadays. All these adverse outcomes
are closely related to poor glycemic control during the
organogenesis period and unfortunately are still very
prevalent. Hyperglycemia during the periconceptional
period is probably the major teratogenic existing fac-
tor, but obesity, hypertension and other factors asso-
ciated with the metabolic syndrome might also be
relevant [1].l Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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Normal pregnancy is a non pathological condition charac-
terized by a series of complex hormonal adaptations that
occur to ensure that sufficient glucose is available to meet
the nutritional requirements of the growing fetus without
causing maternal hypoglycemia. Hyperglycemia, a hall-
mark of diabetes, is an important cause of maternal and
fetal complications in pregnancies of women with any type
of diabetes. Generally, the pregnancy in women with dia-
betes is associated with increased risk of obstetric and
neonatal complications, morbidity and mortality [1-19].
The most common fetal adverse outcomes found in
pregnancies of women with diabetes are fetal and neo-
natal loss, a great variety of congenital abnormalities and
malformations, premature delivery (delivery occurring
before 37 weeks’ gestation), fetal growth acceleration and
macrosomia (defined as a birth weight above 4 kg and/
or >90th percentile weight for gestational age or large
for gestational age) which are associated with several ob-
stetric complications like birth trauma, hypertrophic
miocardiopathy, stillbirth, respiratory distress syndrome,
neonatal hypoglycemia, hypocalcemia, hyperbilirubine-
mia and polycythemia; maternal complications are preg-
nancy induced hypertension, pre-eclampsia, hemolysis,
elevated liver enzymes, low platelets (HELLP) syndrome,
Cesarean section, hypoglycemia and the worsening of
any degree of a pre-existing renal insufficiency and retin-
opathy [20,21].
Fetal adverse outcomes
Pregnancy loss is significantly higher among women
with diabetes compared to the nondiabetic population
[14]. Recently, a population-based cohort study con-
ducted in the UK by Casson et al. has shown that
women with type 1 diabetes have a higher risk of late
fetal loss, presenting a four- to five-fold increase in peri-
natal death, and a four- to six-fold in stillbirth [8] com-
pared to the general population. Neonatal mortality is
also higher among infants of diabetic mothers in ap-
proximately 15-fold when compared to the general
population [14].
Schaefer et al. have found a two-fold increase in the
risk of congenital anomalies when fasting glucose levels
are already greater than 120 mg/dL when first detected
during pregnancy [22]. The increased risk of congenital
abnormalities found in diabetic mothers seems to be
associated to poor metabolic control during the period
of organogenesis that occurs in the first trimester of
pregnancy probably due to the negative impact of a
hyperglycemic milieu in the growing fetus [23].
The pathogenesis of congenital malformations of all
types, which have four to ten times higher incidence in
pregnant women with diabetes, is very complex and haspossibly a multifactorial origin [8,14,23]. A strong link
between hyperglycemia and malformations has been
established, but the precise mechanism by which it
occurs has not been completely elucidated. It is sup-
posed that hyperglycemia could cause damage to the
developing yolk sac, an increased production and liber-
ation of free oxygen radicals, deficiency of myoinositol
and arachidonic acid and a disruption in signal transduc-
tion; increasing evidences suggest that embriopathies
might be connected to a disruption in intracellular sig-
naling by inositol-derived effectors and prostaglandin
precursors such as arachidonic acid. Also, a as a result
of the presence of these fuels, some type of genotoxic ef-
fect might occur which could cause morphologic
damages in the fetus [23-27].
Nowadays, there is compelling evidence linking epigen-
etic factors to many human diseases including diabetes.
Epigenetic factors, by different types of reactions, could
mediate the interplay between genes and environment
resulting in activation or repression of genetic transcrip-
tion, or even silencing the genetic transcription. The most
important epigenetic reactions affecting genetic transcrip-
tion are acetylation and methylation. These reactions
occur mainly in the tail of histones that are proteins where
DNA is wrapped. Brownlee et al. [28] have demonstrated
in human aortic endothelial cells, that excessive concen-
tration of reactive oxygen species (ROS) resulting from
hyperglycemia can induce monomethylation of lysine
from histone 3 increasing the expression of the subunit
p65 of nuclear factor kappa beta. This reaction is respon-
sible for the increased transcription of vascular cell adhe-
sion molecule 1 and monocyte chemoattractant molecule
1 (MCP1) that are both related to hyperglycemia-induced
arterial pathology [28]. However, this reaction persisted
after a six days period of subsequent normoglycemia, sup-
porting the concept of metabolic memory. Another study
showed an increase of DNA methylation in insulin pro-
moter DNA in human pancreatic islets which was
negatively correlated with insulin gene expression and
positively correlated with HbA1c levels [29].
Specifically concerning GDM, some epigenetic altera-
tions have been described recently mainly related to beta
cell function and intrauterine growth retardation. These
alterations could result in reduction of expression of
PDX-1, a transcription factor that regulates beta cell de-
velopment [30]. Although further studies are necessary
to establish the possible role of PDX-1 in GDM, it is im-
portant to note that epigenetic effects are defined as her-
itable changes to DNA structure that do not involve
changes to the DNA sequence; being so, they can be re-
set or undone under certain conditions such as in early
development [30]. Previous studies showed that folic
acid, that is a methyl donor, prevents genomic damage
in human lymphocytes in vitro and maybe also the
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effects on the human genome [31].
Recently, the effect of folic acid on human reproduction
has been well reviewed and the relationship between folate
with vitamin B12 upon DNA synthesis and methylation
has been demosntrated [32]. Randomized trials have
shown that periconceptional supplementation with folic
acid can reduce the frequency of midline embryonic
defects, as well as heart defects, orofacial clefts and mis-
carriages [32,33]. During pregnancy, folic acid require-
ments increase due to expansion of maternal erythrocyte
number, uterine enlargement, placental development and
fetal growth [33]. Folic acid deficiency during gestation is
associated with impaired cellular growth and replication
that can result in megaloblastic anemia, spontaneous
abortions, fetal malformations, placental abruption, pre-
term delivery and low birth weight [32]. Many Medical
Societies like the American College of Obstetricians and
Gynecologists [34] and Canadian Obstetrical Societies
[35] recommend high-dose folic acid supplementation
(4–5 mg/day) in diabetic women before and during preg-
nancy aiming to reduce the risk of congenital malforma-
tions in their babies; this dose is ten times higher than
those recommended for non diabetic women [34,35].
The major congenital malformations among offspring
of women with diabetes are found in the following sys-
tems: cardiovascular (cardiac transposition of the great
arteries, ventricular septal defect, coarctation of the
aorta, atrial septal defect, asymmetric septal hypertrophy),
central nervous system (neural tube defects, including an-
encephaly, microcephaly and isolated hydrocephalus),
gastrointestinal (duodenal atresia, anorectal atresia, hypo-
plastic left colon), musculoskeletal (talipes, arthrogryposis),
urinary tract (uretal duplication, cystic kidney, renal dys-
genesis, hydronephrosis), caudal regression syndrome, cleft
lips and palate anomalies [9,20]. These major congenital
abnormalities are an important contributory factor for the
high mortality rates found in infants of women with dia-
betes [8]. Preterm delivery is four to five times higher
among mothers with diabetes [3]. Generally, babies of
mothers with diabetes tend to fare less well at all stages of
the pregnancy. The possibility of a premature delivery is al-
ways strived by the health care team as much as possible,
but this is not always possible. In the presence of signifi-
cant complications, the mother’s and the babies’ health is
paramount and early delivery may become a life-saving
measure [3]. Preterm infants born to women with any type
of diabetes, have a much greater risk of presenting a wide
range of complications such as, intrauterine growth restric-
tion, low-birth-weight, respiratory distress syndrome,
hypoglycemia, hypocalcemia, polycythemia, intrauterine
death, hyperbilirubinemia, several types of malformations,
hypertrophic cardiomyopathy and asphyxia compared to
those born to women without diabetes [1,3].Glucose is transported freely across the placenta by
facilitated diffusion; in the presence of maternal hyper-
glycemia large amounts of glucose reach the fetus which
leads to fetal hyperinsulinemia that causes fetal over-
growth and/or macrosomia. Increased glucose levels,
even those below the threshold for gestational diabetes,
for example, are associated with continuous increase in
the risk of macrosomia and Cesarean section as described
by Sermer et al. [36] and by the Hyperglycemia and Ad-
verse Pregnancy Outcomes (HAPO) Study [37]. Any de-
gree of hyperglycemia that the fetal tissues are exposed to,
stimulates insulin secretion that can cause hypertrophy of
insulin-sensitive tissues such as adipose tissue, skeletal
and myocardial muscle, hepatic tissues and even islets of
Langherhans in the pancreas; as a result, an accelerated
fetal growth can be found and eventually macrosomia. Be-
sides high blood glucose levels, high levels of other meta-
bolic fuels such as some aminoacids and free fatty acids
might as well increase fetal insulin secretion after beta cell
replication [38,39].
The great majority of macrosomias (70%) are due to
constitutional and genetic factors, prolonged pregnan-
cies or to some syndromes [40]. Macrosomias occurring
in children of mothers with diabetes correspond to 30%
of the cases; these macrosomias are classically dys-
morphic with a greater growth of shoulders and abdo-
men in relation to head [41], what increases the risk of
several obstetric complications, such as higher rates of
Cesarean section, shoulder dystocia, chorioamnionitis,
severe perineal lacerations and postpartum hemorrhage
[17,19]. The rates of macrosomia are 3.5–4.5 times
greater among infants of women with pregestational dia-
betes than those found in infants born to nondiabetic
mothers [17,19].
The newborn’s heart has a great amount of insulin
receptors. In a state of hyperinsulinism such as gesta-
tional diabetes, a hypertrophic miocardiopathy can
occur; this condition is characterized by hypertrophy of
the septum and ventricular walls that can in some cases
obstruct blood flow. It can be asymptomatic, in some
instances cause cardiac failure or regress in the first
months of life. It is also thought to be an important
cause of intrauterine death and stillbirth [42].
The excess of insulin in the fetal circulation can delay
pulmonary maturation associated with the low produc-
tion of surfactant leading to the respiratory distress syn-
drome or hyaline membrane disease. This condition is
about six-fold more frequently found in newborns of
women with diabetes than in nondiabetic women [43].
Hypoglycemia is the most common neonatal compli-
cation that occurs in diabetic pregnancies. Right after
the section of the umbilical cord, the deprivation of ma-
ternal glucose supply, can lead to this condition that
generally happens in the first hours of life. It can be
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and even convulsions. It must be prevented and recog-
nized early because it can have severe implications for
the newborn’s immediate and future health [39,44].
Also after the section of the umbilical cord, the deprivation
of maternal nutrient flow, can lead to hypocalcemia
(Ca++ <7 mg/dL) and hypomagnesiemia (Mg++ <1.5 mg/
dL); these conditions also generally happen in the first hours
of life and can cause neuromuscular excitability, irritability,
apnea and even convulsions [39,45,46].
Chronic hyperinsulinemia can lead to an increased
erythropoiesis and also to an accelerated hemolysis due to
glycation processes, that associated to prematurity, modi-
fied hepatic conjugation and modification of the entero-
hepatic circulation, that are frequently found in newborns
to mothers with diabetes, can lead to hyperbilirubinemia
(bilirubin >13 mg/dL); this condition is two-fold more fre-
quently found in newborns of mothers with diabetes com-
pared to the background population [47].
Generally, the placental blood flow is impaired and
transplacental exchanges are poor in the presence of
hyperglycemia and hyperinsulinemia and a state of chronic
relative hypoxemia occurs. Under the acute and chronic
stimulus of hypoxia, extramedullary erythopoiesis is acti-
vated and a consequent polycythemia develops. It is diag-
nosed by a venous hematocrit > 65% or hemoglobin
> 20 g/dL. This occurs in about 30% of newborns of
mothers with diabetes [48].
The metabolic risks for the infants of mothers with
diabetes extends much longer after birth; the influence
of the maternal in utero environment is evidenced in the
U- or J-shaped relationship between birth weight and
adult obesity and metabolic disease demonstrating that
both a limited or excessive nutritionally intrauterine en-
vironment can lead to postnatal obesity and related
chronic diseases, like type 2 diabetes, hypertension and
metabolic syndrome. This might result in a vicious cycle
that could explain the great increase in the rates of obes-
ity, gestational diabetes and type 2 diabetes seen in the
last decades [38,49,50].Maternal adverse outcomes
On the maternal side, morbidity and mortality rates are
also higher among pregnant women with diabetes. Rates
of pre-eclampsia (12.7%), Cesarean section (44.3%) and
maternal mortality (0.6%) found among women with type
1 diabetes are considerably higher than in the background
population. Hypertension and postpartum hemorrhage
are more likely to be found in pregnancies complicated by
diabetes [1,3]. Pregnant women with type 1 diabetes
present a death rate 109 times greater than the general
population and 3.4 times greater than in nonpregnant type
1 diabetic women [18].Changes in glucose disposal and insulin kinetics seen
in pregnancy have special importance for women with
pregestational diabetes because hypoglycemia, many
times of severe intensity, can occur generally in early
pregnancy, a period when insulin requirements may de-
crease, possibly because of nausea and vomiting, com-
pared to prepregnancy and to the second half of
pregnancy; it is a dangerous condition that can leave im-
portant sequellae to the mother and the fetus [51].
The prevalence of chronic hypertension, gestational
hypertension, pre-eclampsia, and superimposed pre–
eclampsia are all more frequent in diabetic pregnancies.
The presence of chronic hypertension, microalbuminuria
or diabetic nephropathy should be evaluated in early
pregnancy. All pregnant diabetic women should receive
strict metabolic control and be intensively monitored for
the development of pre–eclampsia and pregnancy induced
hypertension because these conditions can cause a nega-
tive impact for the mother’s and the fetus’ health [52].
Patients presenting moderate -to- severe renal insuffi-
ciency and uncontrolled hypertension prior to conception
and/or early in pregnancy show an increased risk for
accelerated progression to end-stage renal disease. The
perinatal survival is high (> 95%) in patients with min-
imal renal dysfunction (serum creatinine < 125 μ mol/L
[ < 1.4 mg/dL]); however, pre-eclampsia and preterm
delivery are very common conditions found in this group
of patients [53].
Diabetic retinopathy, a very prevalent microvascular
complication of diabetes, remains the leading cause of
acquired blindness in young and middle - aged adults in
the world. Pregnancy, a condition that presents hormonal,
hemodynamic, metabolic, and immunologic changes, is a
risk factor for progression of diabetic retinopathy. The eti-
ology of retinopathy acceleration during pregnancy is still
unknown; proposed mechanisms involve rapid improve-
ment in glycemic control, altered hemodynamic proper-
ties, with the reduction of blood flow in the retina and
immuno-inflammatory processes [54].
Conclusion
Pregnancy should be planned in women with preexisting
diabetes, which includes a strict metabolic control with
near or near-normal glucose levels, reached through life-
style modifications, a healthy diet, and an exercise plan-
ning program with the supplementation of folic acid that
is advocated to prevent malformations and miscarriages.
Future research is warranted in this field and two areas
must be addressed. First, there are the social issues
related to diabetes in pregnancy, in women with preex-
isting diabetes and in those with gestational diabetes.
There is a need to increase knowledge on reproductive
health of these women and to understand what are the
reasons for them failing to attend for prepregnancy care,
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more appropriate facilities and methods which should
improve uptake and the final results. Another social
issue is trying to address the obesity epidemic which is
directly related to the occurrence of gestational diabetes
and may increase the risk of malformations, and may
also make their antenatal detection and diagnosis more
difficult. The second area is for emphasizing the import-
ance of basic research into the mechanisms causing ad-
verse fetal and maternal outcomes, which in turn may
lead to more efficient strategies for their prevention.
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